AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors

Abstract Background Non-small cell lung cancer (NSCLC) is a significant global health challenge, with 2% of cases fuelled by RET rearrangements. RET inhibitors (RETi) have revolutionized treatment for these patients, but resistance remains an important clinical challenge limiting therapy effectivene...

全面介紹

書目詳細資料

Principais autores:	Daniela Esposito, Claudia Maria Ascione, Stefania Belli, Fabiana Napolitano, Alberto Servetto, Felice Pepe, Umberto Malapelle, Antonino Iaccarino, Giancarlo Troncone, Diletta Barone, Emilio Bria, Roberto Ferrara, Daniele Lorenzini, Giuseppe Lo Russo, Maria Rosa Ghigna, Arianna Marinello, Mihaela Aldea, Benjamin Besse, Luigi Formisano, Roberto Bianco
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-05-01
叢編:	Journal of Experimental & Clinical Cancer Research
主題:	Non-small cell lung cancer RET RET inhibitors EGFR Drug resistance Combination targeted therapy
在線閱讀:	https://doi.org/10.1186/s13046-025-03392-w
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!